What advantages does a dead-space-free design offer for hygienic mixing in the pharmaceutical industry?
A dead-space-free design reduces areas in which product residues, cleaning media or process liquids can stagnate. It is a central principle of hygienic plant design in pharmaceutical production and supports product safety, cleanability and regulatory compliance.
Important advantages
Less cross-contamination
Dead spaces, gaps and cavities that are difficult to access can retain residues and lead to carry-over during batch changes. A dead-space-free geometry improves complete discharge and facilitates controlled batch changeover.
Better CIP and SIP capability
For effective cleaning-in-place and sterilise-in-place processes, all product-contact surfaces must be reached reliably. A dead-space-free design facilitates wetting, through-flow and validation and can reduce cleaning times, media consumption and energy input.
Higher microbiological safety
Zones of stagnation promote biofilm formation and microbial growth. The fewer inactive areas there are, the lower the risk of critical contamination, particularly in sterile and aseptic applications.
More stable product quality
A hygienic, flow-optimised geometry supports uniform product treatment and can avoid unwanted residual zones or local segregation. This is particularly important where content uniformity and reproducible process management are required.
Higher yield
Where less product remains in cavities, material losses fall. This is economically relevant above all with high-priced or highly potent active ingredients.
Easier validation and documentation
Smooth, easily accessible geometries facilitate riboflavin tests, swab and rinse sampling and cleaning validation as a whole. This supports qualification and GMP-compliant documentation.
Better compatibility with standards and GMP
Dead-space-free designs help to implement requirements from EHEDG, ASME BPE and GMP in practice. The details are considered on a risk basis and assessed in the particular application context.
In brief
A dead-space-free design improves hygiene, cleanability, product safety and process stability while reducing contamination risks and product losses. It is therefore a central quality feature of hygienic mixing technology in pharmaceuticals.
How amixon® implements dead-space-free construction and hygienic design
Freedom from dead space as a design principle
In amixon® precision mixers such as VM, HM, AM, KoneSlid® and Gyraton®, the mixing chamber and mixing tool are welded free of crevices and ground smooth. In the product-contact area there are no gaps, screwed joints or capillary crevices. The mixing tool is supported and driven exclusively from above, so that the lower shaft passage, classically critical for contamination, is eliminated entirely.
The standard connection with a discharge flap closes flush and free of dead space with the inner wall of the mixing chamber; dead-space-free ball segment fittings are available as an alternative. The large inspection doors are manufactured by the Clever-Cut® process and seal permanently free of dead space with the OmgaSeal® door seal – vacuum-tight or against overpressure on request.
Cleaning and accessibility
Integrated washing lances allow wet cleaning of the mixing chamber; on request amixon® also supplies fully automatic wet cleaning systems. The SinConvex® mixing tool supports the complete drainage of product and cleaning medium. The design is laid out for both dry and wet cleaning regimes.
The Clever-Cut® doors provide complete, ergonomic access to all product-contact surfaces and thus create the basis for visual cleaning inspection as well as sampling by swab or rinse.
Certifiability and evidence
On request, amixon® mixers meet the EHEDG guidelines, the FDA hygiene guidelines, the design rules of the 3-A Sanitary Standards and GMP requirements. VM, HM and other suitable designs can be used in FDA-compliant form as sterile mixers and reactors. With free-flowing materials, ComDisc® residual discharge can markedly reduce residues and cross-contamination risks during formulation changes.
For pharmaceutical applications, amixon® supplies the apparatus in GMP-compliant form and assists on request with DQ, IQ and OQ as well as documentation to EU GMP and FDA 21 CFR Part 11. Every apparatus is designed as a one-off to the operator's URS.
Manufacture in Paderborn as the quality foundation
amixon® develops and manufactures exclusively at the Paderborn works with a high depth of manufacture and all components from Germany. As a certified welding company with European, Japanese, Korean and American qualifications, amixon® designs every apparatus as a one-off on the basis of the operator's URS; quality control remains entirely in-house without gaps, and every specification is verifiable down to component level. This manufacturing autonomy also secures long-term supply, since every component can still be re-manufactured reproducibly decades later.
Product protection as a system property
amixon® mixers operate at low speed. The circumferential speed of the tools is adjustable between approximately 0.8 and 3.5 m/s; mixing takes place through SinConvex® forced restratification – upwards at the periphery, downwards under gravity in the centre – without throwing, impact or crushing zones and without appreciable heat input. Sensitive structures, coatings and agglomerates are preserved; where targeted de-agglomeration is required, switchable cutting rotors act in a locally limited manner without stressing the entire batch.
Verification in the amixon® pilot plant
Whether the specific formulation delivers the expected results is verified by amixon® in advance at the pilot plant with 35 test units under real conditions. The trials are run with the original product, carried out, evaluated and documented jointly and form a robust basis for decision-making before the investment.